Bepotastine
An antihistamine used to relieve itching of the eyes caused by allergic conjunctivitis. It works by blocking histamine receptors and may also stabilize mast cells to reduce allergic responses. It is typically applied as eye drops for quick, targeted relief.
Molecular Weight
388.9000 g/mol
LogP
1.00
TPSA
62.70 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
2D Structure
Cite this structure
Embed this structure
SMILES
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1
InChI
InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1
Molecular Formula
C21H25ClN2O3
HBD / HBA
1 / 5
Rotatable Bonds
8
Heavy Atoms
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An antihistamine used to relieve itching of the eyes caused by allergic conjunctivitis. It works by blocking histamine receptors and may also stabilize mast cells to reduce allergic responses. It is typically applied as eye drops for quick, targeted relief.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Bepotastine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201758. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 164522. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bepotastine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bepotastine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bepotastine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bepotastine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bepotastine"></drugfyi-drug>